Published in:
01-06-2016 | Special Article
Japan Society of Gynecologic Oncology guidelines 2013 for the treatment of uterine body neoplasms
Authors:
Yasuhiko Ebina, Hidetaka Katabuchi, Mikio Mikami, Satoru Nagase, Nobuo Yaegashi, Yasuhiro Udagawa, Hidenori Kato, Kaneyuki Kubushiro, Kiyoshi Takamatsu, Kazuhiko Ino, Hiroyuki Yoshikawa
Published in:
International Journal of Clinical Oncology
|
Issue 3/2016
Login to get access
Abstract
The third version of the Japan Society of Gynecologic Oncology guidelines for the treatment of uterine body neoplasms was published in 2013. The guidelines comprise nine chapters and nine algorithms. Each chapter includes a clinical question, recommendations, background, objectives, explanations, and references. This revision was intended to collect up-to-date international evidence. The highlights of this revision are to (1) newly specify costs and conflicts of interest; (2) describe the clinical significance of pelvic lymph node dissection and para-aortic lymphadenectomy, including variant histologic types; (3) describe more clearly the indications for laparoscopic surgery as the standard treatment; (4) provide guidelines for post-treatment hormone replacement therapy; (5) clearly differentiate treatment of advanced or recurrent cancer between the initial treatment and the treatment carried out after the primary operation; (6) collectively describe fertility-sparing therapy for both atypical endometrial hyperplasia and endometrioid adenocarcinoma (corresponding to G1) and newly describe relapse therapy after fertility-preserving treatment; and (7) newly describe the treatment of trophoblastic disease. Overall, the objective of these guidelines is to clearly delineate the standard of care for uterine body neoplasms in Japan with the goal of ensuring a high standard of care for all Japanese women diagnosed with uterine body neoplasms.